A class action lawsuit has been filed against Insulet Corporation alleging that the company made materially false and misleading statements regarding its business operations and compliance policies. The complaint specifically claims that Insulet's manufacturing controls were defective, creating a foreseeable risk that products could violate safety regulations. Investors who purchased Insulet securities between May 21, 2025 and May 26, 2026 are eligible to join the case, with a lead plaintiff deadline of August 31, 2026.

Pomerantz LLP has filed a class action lawsuit against Insulet Corporation for alleged securities fraud. The complaint alleges that Insulet made false statements about its manufacturing controls and failed to disclose defective procedures that created safety risks. Two voluntary medical device corrections were announced in March and May 2026, resulting in significant stock price declines of 6.88% and 5.07% respectively.

Rosen Law Firm is reminding investors who purchased Insulet Corporation securities between February 21, 2025 and May 26, 2026 of the August 31, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that Insulet made false statements regarding defective manufacturing controls and procedures that created safety risks, resulting in investor damages.

Law Offices of Howard G. Smith has announced securities fraud class action lawsuits against four publicly-traded companies: Futu Holdings Limited, Hub Group Inc., Insulet Corporation, and Photronics Inc. The lawsuits allege that defendants made false or misleading statements regarding regulatory compliance, financial accuracy, manufacturing controls, and business operations. Investors have until late August and early September 2026 to file lead plaintiff motions.

The global blood glucose monitoring system market is valued at USD 16.8 billion in 2025 and is projected to reach USD 39.4 billion by 2035, growing at a CAGR of 8.9%. Growth is driven by AI-enabled monitoring systems, increasing diabetes prevalence, and rising adoption of home healthcare solutions. Key players include Medtronic, Abbott, Dexcom, and Roche, with recent partnerships like Abbott-Medtronic collaboration to integrate continuous glucose monitoring with automated insulin delivery systems.

Insulet Corporation faces a securities class action lawsuit over defective cannula manufacturing in Omnipod insulin delivery devices. Approximately 7 million Pods were affected by manufacturing defects causing insulin under-delivery. The stock declined from $236 to $146.01 per share following two Medical Device Corrections. Investors who purchased securities between February 21, 2025 and May 26, 2026 may be eligible for compensation, with a lead plaintiff deadline of August 31, 2026.

Rosen Law Firm has filed class action lawsuits on behalf of investors in Insulet Corporation (PODD), GRAIL, Inc. (GRAL), and GeneDx Holdings Corp. (WGS). The lawsuits allege that defendants made false or misleading statements regarding manufacturing controls, product safety compliance, and regulatory risks. Investors who purchased securities during the specified class periods may be eligible for compensation. The lead plaintiff deadline is August 31, 2026.

A securities class action lawsuit has been filed against Insulet Corporation alleging the company made false and misleading statements about its manufacturing controls and procedures. The lawsuit covers investors who purchased Insulet securities between February 21, 2025 and May 26, 2026. Two voluntary medical device corrections were disclosed in March and May 2026 involving manufacturing issues with Omnipod products, resulting in significant stock price declines. The deadline to seek lead plaintiff status is August 31, 2026.

The Schall Law Firm is seeking investors who purchased Insulet Corporation (NASDAQ: PODD) securities between February 21, 2025 and May 26, 2026 to join a class action lawsuit alleging securities fraud. The lawsuit claims Insulet made false and misleading statements regarding defective manufacturing controls, increased safety violation risks, and understated the scope of its March 2026 Medical Device Correction affecting Pod Products.

A class action lawsuit has been filed against Insulet Corporation alleging that the company made materially false and misleading statements regarding its business operations and compliance policies. The complaint specifically claims that Insulet's manufacturing controls and procedures were defective, creating a foreseeable risk that products could violate safety regulations. Investors who purchased Insulet securities between May 21, 2025 and May 26, 2026 are encouraged to join the case, with a lead plaintiff deadline of August 31, 2026.

The Rosen Law Firm is investigating potential securities claims against GoDaddy Inc., Wise Group plc, and Insulet Corporation on behalf of shareholders, alleging these companies issued materially misleading business information. Investors who purchased securities in these companies may be entitled to compensation through class action lawsuits.

Rosen Law Firm has filed a class action lawsuit against Insulet Corporation (PODD) on behalf of investors who purchased securities between February 21, 2025 and May 26, 2026. The lawsuit alleges that Insulet made false and misleading statements regarding defective manufacturing controls and procedures that created a foreseeable risk of safety violations. Investors who wish to serve as lead plaintiff must file by August 31, 2026.